Filing Flows › Bristol Myers Squibb (BMY) › Guidance & outlook
Bristol Myers Squibb (BMY) guidance and outlook
Bristol Myers Squibb (BMY) raised some and lowered other parts of its guidance on Oct 29, 2026: Revenue $49.8B–$50.2B for FY2026; EPS $6.35–$6.55 for FY2026; Gross margin 69%–70% for FY2026; Other income −$700M for FY2026. Bristol Myers Squibb's 10-Q filed Oct 29, 2026 makes 7 forward-looking statements, 1 of them new and 0 no longer said since the filing before.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $49.8B–$50.2B | raised |
| EPS | FY2026 | $6.35–$6.55 | lowered |
| Revenue | FY2026 | $49.8B–$50.2B | raised |
| Gross margin | FY2026 | 69%–70% | reaffirmed |
| Other income | FY2026 | −$700M | reaffirmed |
| Tax rate | FY2026 | 18% | reaffirmed |
| EPS | FY2026 | $6.75–$7.00 | raised |
| Revenue | FY2026 | +20% to +25% | new |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 29, 2026
- new · Additionally, in August 2026, we announced plans to build a new, state-of-the-art multi-modal manufacturing campus in Houston, Texas, and a new, radiopharmaceutical manufacturing facility in Whitestown, Indiana, reflecting our continuing efforts to invest in research and development, technology and domestic production within the U.S.
- As a result of an expansion in 2025, we expect to realize annual cost savings of approximately $2.0 billion by the end of 2027.
- We believe in the innovative science behind Eliquis and the strength of our intellectual property, which we will defend against infringement.
- We disclose products with levels of inventory in excess of one month on hand or expected demand, subject to certain limited exceptions.
- Factors that may affect our estimates include generic competition, seasonality of products, price increases, new product launches, new warehouse openings by direct customers, new customer stockings by direct customers and expected direct customer purchases for governmental bidding situations.
- We will disclose any product with levels of inventory in excess of one month on hand or expected demand for the current quarter, subject to certain limited exceptions, in our next annual report on Form 10-K.
- Non-GAAP information is intended to portray the results of our baseline performance, supplement or enhance management's, analysts' and investors’ overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods.
Bristol Myers Squibb's latest quarter
Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
Questions
Did Bristol Myers Squibb raise or lower its guidance?
Bristol Myers Squibb (BMY) raised some and lowered other parts of its guidance on Oct 29, 2026: Revenue $49.8B–$50.2B for FY2026; EPS $6.35–$6.55 for FY2026; Gross margin 69%–70% for FY2026; Other income −$700M for FY2026.
What does Bristol Myers Squibb expect?
Additionally, in August 2026, we announced plans to build a new, state-of-the-art multi-modal manufacturing campus in Houston, Texas, and a new, radiopharmaceutical manufacturing facility in Whitestown, Indiana, reflecting our continuing efforts to invest in research and development, technology and domestic production within the U.S.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.